Axonics (NASDAQ:AXNX – Get Rating) had its price objective hoisted by Needham & Company LLC from $60.00 to $77.00 in a research note released on Tuesday morning, The Fly reports. Needham & Company LLC currently has a buy rating on the stock. Several other research analysts have also recently issued reports on AXNX. Truist Financial […]
Zacks Investment Research upgraded shares of Axonics (NASDAQ:AXNX – Get Rating) from a sell rating to a hold rating in a research note published on Friday morning, Zacks.com reports. According to Zacks, “Axonics Modulation Technologies Inc. is focused on development and commercialization of a novel implantable SNM system for patients with urinary and bowel dysfunction […]